Search

In recognition of Breast Cancer Awareness Month, MSK shared four stories about new developments and advances in breast cancer prevention, research and treatment being conducted by MSK clinicians and researchers.

… Wednesday, October 20, 2021 In recognition of Breast Cancer Awareness Month, Memorial Sloan Kettering Cancer Center (MSK) shared four stories about new developments and advances in breast cancer prevention, research and treatment being conducted by MSK clinicians and researchers. The COVID-19 pandemic

MSK's Chair of the Department of Surgery discusses what people need to know about rescheduling treatment and what we're doing to keep you safe.

… Wednesday, August 12, 2020 Summary MSK’s Chair of the Department of Surgery discusses what people need to know about rescheduling treatment and what we’re doing to keep you safe. As fewer people in New York are being hospitalized due to COVID-19 complications and restrictions have been lifted, all types

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Integrative Medicine, Jun J. Mao, MD, MSCE will be presenting a new study comparing the effectiveness of electro-acupuncture (EA) and auricular acupuncture (AA) versus usual care (UC) for chronic musculoskeletal pain in cancer survivors.

… Thursday, May 28, 2020 Dr. Jun Mao Dr. Jun Mao At the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program , MSK’s Chief of Integrative Medicine, Jun J. Mao, MD, MSCE will present a new study comparing the effectiveness of electro-acupuncture (EA) and auricular acupuncture

Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts.

… Monday, February 11, 2013 Summary Researchers have clarified the process by which developing nerve cells are directed to specialize into distinct parts. Memorial Sloan Kettering researchers have shed light on the process by which developing nerve cells, or neurons, are directed to split into two distinct

The findings could pave the way toward more targeted treatments for the disease.

… Friday, May 27, 2022 A previously unknown subtype of hormone-resistant prostate cancer accounts for about 30% of all cases, according to a new study from a team of scientists at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine, published May 27, 2022, in the journal Science . The

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.

… Monday, December 30, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Arvin Dar Elected to the National Academy of Inventors 2024 Class of Fellows Arvin Dar Elected to the National Academy of Inventors 2024 Class of Fellows Arvin Dar, PhD , Benno

New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.

… Wednesday, May 14, 2014 A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance

As America commemorates the 50th anniversary of the “War on Cancer,” MSK addresses the question “Where do we go from here?”

… Thursday, April 1, 2021 This year marks the 50th anniversary of the “War on Cancer,” launched when President Richard Nixon signed the National Cancer Act in 1971. As America commemorates the milestone, the question for the future is: “Where do we go from here?” At Memorial Sloan Kettering, the direction

There are new, FDA-authorized treatment options for people facing esophageal and gastric (stomach) cancer, thanks to clinical trials at Memorial Sloan Kettering that combined immunotherapy with standard treatments.

… Wednesday, March 23, 2022 Dr. Yelena Janjigian hugs MSK patient Cecilia Defoe Cecilia Defoe (left) with MSK oncologist Yelena Janjigian. Cecilia says of Dr. Janjigian, “She’s part of my extended family now. Everybody in my family knows her, including my mom and my sisters. She’s a gem.” Scroll right

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  

… Wednesday, January 31, 2018 Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor ( CAR ) T cell therapy responded better if they had a small amount of disease